September 15, 2026 · Phase 3 readout
MRK Phase 3 readout: a positive outcome, +12.6%
+12.6%MERCK (MRK) →
On September 15, 2026, Cisplatin (as radiosensitizer) — MERCK (Endometrial Neoplasms) reached its Phase 3 readout. The result was a positive outcome, and the stock moved +12.6% in the window around the event. It had already run +9.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$135.17
1d before
$152.20
Event day
$148.99
1d after
$150.66
5d after
Pre-catalyst setup
+9.2%
30-day run-up
1655%
30-day volatility
1.2×
volume spike